• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MV140黏膜细菌疫苗可改善尿路感染实验模型中尿路致病性细菌的清除情况。

MV140 mucosal bacterial vaccine improves uropathogenic clearance in an experimental model of urinary tract infection.

作者信息

Saz-Leal Paula, Ligon Marianne M, Diez-Rivero Carmen M, García-Ayuso Diego, Mohanty Soumitra, Conejero Laura, Brauner Annelie, Subiza José L, Mysorekar Indira U

机构信息

Inmunotek, S.L. Alcalá de Henares, Madrid, Spain.

Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, USA.

出版信息

Res Sq. 2023 Jun 7:rs.3.rs-2992611. doi: 10.21203/rs.3.rs-2992611/v1.

DOI:10.21203/rs.3.rs-2992611/v1
PMID:37333312
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10275044/
Abstract

MV140 is a mucosal vaccine of inactivated whole bacteria () with clinical efficacy against recurrent urinary tract infections (UTIs). Here, MV140 was evaluated in a murine model of acute uropathogenic (UPEC)-induced UTI using the UTI89 strain. MV140 vaccination resulted in UPEC clearance, concomitant with increased influx of myeloid cells in urine, CD4+ T cells in the bladder, and a systemic adaptive immune response to both MV140-containing and UTI89.

摘要

MV140是一种灭活全菌粘膜疫苗，对复发性尿路感染（UTI）具有临床疗效。在此，使用UTI89菌株在急性尿路致病性大肠杆菌（UPEC）诱导的UTI小鼠模型中对MV140进行了评估。MV140疫苗接种导致UPEC清除，同时尿液中髓样细胞、膀胱中CD4 + T细胞的流入增加，以及对含MV140制剂和UTI89的全身适应性免疫反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307f/10275044/d2c4df289a1e/nihpp-rs2992611v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307f/10275044/337381b0ba3d/nihpp-rs2992611v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307f/10275044/d2c4df289a1e/nihpp-rs2992611v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307f/10275044/337381b0ba3d/nihpp-rs2992611v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307f/10275044/d2c4df289a1e/nihpp-rs2992611v1-f0002.jpg

相似文献

1
MV140 mucosal bacterial vaccine improves uropathogenic clearance in an experimental model of urinary tract infection.MV140黏膜细菌疫苗可改善尿路感染实验模型中尿路致病性细菌的清除情况。
Res Sq. 2023 Jun 7:rs.3.rs-2992611. doi: 10.21203/rs.3.rs-2992611/v1.
2
MV140 Mucosal Vaccine Induces Targeted Immune Response for Enhanced Clearance of Uropathogenic in Experimental Urinary Tract Infection.MV140 粘膜疫苗在实验性尿路感染中诱导靶向免疫反应以增强对尿路致病性细菌的清除。
Vaccines (Basel). 2024 May 14;12(5):535. doi: 10.3390/vaccines12050535.
3
Photochemical inactivation as an alternative method to produce a whole-cell vaccine for uropathogenic (UPEC).光化学失活作为一种替代方法来生产用于尿路感染（UPEC）的全细胞疫苗。
Microbiol Spectr. 2024 Mar 5;12(3):e0366123. doi: 10.1128/spectrum.03661-23. Epub 2024 Feb 5.
4
Reducing Recurrent Urinary Tract Infections in Women with MV140 Impacts Personal Burden of Disease: Secondary Analyses of a Randomized Placebo-controlled Efficacy Study.使用MV140降低女性复发性尿路感染对疾病个人负担的影响：一项随机安慰剂对照疗效研究的二次分析
Eur Urol Open Sci. 2024 Mar 29;63:96-103. doi: 10.1016/j.euros.2024.03.010. eCollection 2024 May.
5
Intracellular uropathogenic Escherichia coli are undetectable in urinary bladders after oral mecillinam treatment: An experimental study in a pig model of cystitis.口服美西林治疗后，尿路上皮细胞内尿路致病性大肠埃希菌不可检测：膀胱炎猪模型的实验研究。
Microb Pathog. 2022 Dec;173(Pt A):105817. doi: 10.1016/j.micpath.2022.105817. Epub 2022 Oct 14.
6
A Combination of Polybacterial MV140 and V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections.多细菌 MV140 和 V132 联合作为一种潜在的新型基于训练免疫的泌尿生殖道感染疫苗。
Front Immunol. 2021 Jan 21;11:612269. doi: 10.3389/fimmu.2020.612269. eCollection 2020.
7
Secretory leukocyte protease inhibitor protects against severe urinary tract infection in mice.分泌白细胞蛋白酶抑制剂可预防小鼠严重尿路感染。
mBio. 2024 Feb 14;15(2):e0255423. doi: 10.1128/mbio.02554-23. Epub 2024 Jan 25.
8
Secondary Analysis of Interstitial Cystitis/Bladder Pain Syndrome Patients Enrolled in a Recurrent Urinary Tract Infection Prevention Study Provides a Novel Paradigm for Etio-Pathogenesis and Practical Management of This Infection Phenotype.对参与复发性尿路感染预防研究的间质性膀胱炎/膀胱疼痛综合征患者进行的二次分析为这种感染表型的病因发病机制和实际管理提供了一种新的范例。
Pathogens. 2024 May 9;13(5):396. doi: 10.3390/pathogens13050396.
9
Host restriction of Escherichia coli recurrent urinary tract infection occurs in a bacterial strain-specific manner.大肠埃希菌复发性尿路感染的宿主限制以菌株特异性方式发生。
PLoS Pathog. 2018 Dec 13;14(12):e1007457. doi: 10.1371/journal.ppat.1007457. eCollection 2018 Dec.
10
Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection.评估尿路致病性大肠杆菌分离株中FyuA铁受体作为抗尿路感染疫苗靶点的流行率、免疫原性和功效。
Microb Pathog. 2017 Sep;110:477-483. doi: 10.1016/j.micpath.2017.07.037. Epub 2017 Jul 25.

本文引用的文献

1
Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections.舌下含服 MV140 预防复发性尿路感染。
NEJM Evid. 2022 Apr;1(4):EVIDoa2100018. doi: 10.1056/EVIDoa2100018. Epub 2022 Jan 21.
2
V132 induces trained immunity and enhances the responses triggered by the polybacterial vaccine MV140 for genitourinary tract infections.V132 可诱导训练性免疫，并增强多细菌疫苗 MV140 对泌尿生殖道感染的反应。
Front Immunol. 2022 Nov 24;13:1066383. doi: 10.3389/fimmu.2022.1066383. eCollection 2022.
3
A sublingual nanofiber vaccine to prevent urinary tract infections.
舌下纳米纤维疫苗预防尿路感染。
Sci Adv. 2022 Nov 25;8(47):eabq4120. doi: 10.1126/sciadv.abq4120. Epub 2022 Nov 23.
4
Diabetes downregulates the antimicrobial peptide psoriasin and increases E. coli burden in the urinary bladder.糖尿病下调抗菌肽 psoriasin 并增加大肠杆菌在膀胱中的负担。
Nat Commun. 2022 Sep 20;13(1):4983. doi: 10.1038/s41467-022-32636-y.
5
Sublingual Bacterial Vaccination Reduces Recurrent Infections in Patients With Autoimmune Diseases Under Immunosuppressant Treatment.舌下细菌免疫接种可减少接受免疫抑制剂治疗的自身免疫病患者的感染复发。
Front Immunol. 2021 Jun 4;12:675735. doi: 10.3389/fimmu.2021.675735. eCollection 2021.
6
Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future.舌下接种疫苗能否成为加拿大预防复发性尿路感染的可行选择？对当前文献的系统综述及未来规划。
Can Urol Assoc J. 2020 Aug;14(8):281-287. doi: 10.5489/cuaj.6690.
7
The Benefits and Harms of Antibiotic Prophylaxis for Urinary Tract Infection in Older Adults.老年人尿路感染应用抗生素预防的获益与危害。
Clin Infect Dis. 2021 Aug 2;73(3):e782-e791. doi: 10.1093/cid/ciab116.
8
A Combination of Polybacterial MV140 and V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections.多细菌 MV140 和 V132 联合作为一种潜在的新型基于训练免疫的泌尿生殖道感染疫苗。
Front Immunol. 2021 Jan 21;11:612269. doi: 10.3389/fimmu.2020.612269. eCollection 2020.
9
A highly polarized T2 bladder response to infection promotes epithelial repair at the expense of preventing new infections.膀胱对感染的高度极化T2反应以防止新感染为代价促进上皮修复。
Nat Immunol. 2020 Jun;21(6):671-683. doi: 10.1038/s41590-020-0688-3. Epub 2020 May 18.
10
Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review.疫苗在复发性尿路感染中的作用：系统评价。
Eur Urol Focus. 2020 May 15;6(3):593-604. doi: 10.1016/j.euf.2019.11.002. Epub 2019 Dec 2.